Literature DB >> 9228725

Risk formulas in calcium oxalate urolithiasis.

H G Tiselius1.   

Abstract

In order to reflect the risk of calcium stone formation, risk formulas have been described in the literature with the objective of being able to predict the further course of the stone disease. Some of these formulas are reviewed in this paper. Various results were obtained when different risk expressions were related to the severity of the stone disease. Although a reliable prediction of the future course of the disease most certainly cannot be made by analysis of the variables included in these expressions, several of the risk formulas differed significantly between patients with and without recurrent stone formation during a reasonable follow-up period. Some risk formulas might thus be helpful, at least to some extent, in selecting those patients in whom continuous stone formation can be anticipated and in whom active therapeutic measures should be beneficial and worthwhile. With an increased understanding of the mechanisms of calcium oxalate stone formation and our possibilities of measuring the relevant risk factors, it is likely that improved risk formulas with an increased predictive power can be developed. Until this becomes a reality, in most cases we have to combine important information on the history and clinical observations of the disease with a risk formula that offers a high degree of discrimination with respect to the risk of further stone formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228725     DOI: 10.1007/bf02201855

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  37 in total

1.  Urinary excretion of calcium and magnesium in patients with calcium-containing renal stones.

Authors:  R A Evans; M A Forbes; R A Sutton; L Watson
Journal:  Lancet       Date:  1967-11-04       Impact factor: 79.321

2.  Crystallization properties in urine from calcium oxalate stone formers.

Authors:  H G Tiselius; H Bek-Jensen; A M Fornander; M A Nilsson
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

3.  Validity of biochemical findings in the evaluation of patients with urolithiasis.

Authors:  H G Tiselius; L Larsson
Journal:  Eur Urol       Date:  1980       Impact factor: 20.096

4.  Contribution to therapeutic decisions of ratios, absolute values and other measures of calcium, magnesium, urate or oxalate balance in stone formers.

Authors:  G W Drach
Journal:  J Urol       Date:  1976-09       Impact factor: 7.450

5.  Recurrent urolithiasis: a general-practice study of risk factors and clinical consequences.

Authors:  E Laerum
Journal:  Scand J Urol Nephrol       Date:  1984

Review 6.  Effects of citrate on the different phases of calcium oxalate crystallization.

Authors:  H G Tiselius; C Berg; A M Fornander; M A Nilsson
Journal:  Scanning Microsc       Date:  1993-03

7.  [Calcium oxalate activity products and discriminant analysis of urinary parameters as basis for a calcium oxalate screening program (author's transl)].

Authors:  P Brundig; W Berg; J Naumann; H Hoppe; G A Cumme; W Achilles; H J Schneider
Journal:  Urologe A       Date:  1980-01       Impact factor: 0.639

8.  An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.

Authors:  H G Tiselius
Journal:  Clin Chim Acta       Date:  1982-07-15       Impact factor: 3.786

9.  Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis.

Authors:  M Robert; A M Boularan; O Delbos; L Monnier; D Grasset
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

10.  Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers.

Authors:  C Ahlstrand; H G Tiselius; L Larsson; E Hellgren
Journal:  Br J Urol       Date:  1984-06
View more
  28 in total

1.  Evaluating the associations between urinary excretion of magnesium and that of other components in calcium stone-forming patients.

Authors:  Sanaz Tavasoli; Maryam Taheri; Fatemeh Taheri; Abbas Basiri; Fahimeh Bagheri Amiri
Journal:  Int Urol Nephrol       Date:  2018-12-04       Impact factor: 2.370

Review 2.  Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge.

Authors:  Christian Fisang; Ralf Anding; Stefan C Müller; Stefan Latz; Norbert Laube
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

3.  Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1.

Authors:  N Laube; B Hoppe; A Hesse
Journal:  Urol Res       Date:  2005-09-08

4.  The use of risk indices: do they predict recurrence?

Authors:  Roger A L Sutton
Journal:  Urol Res       Date:  2006-01-06

Review 5.  The use of risk indices: do they predict recurrence? Yes, they (at least some) do.

Authors:  Norbert Laube; Michael Pullmann
Journal:  Urol Res       Date:  2006-01-06

Review 6.  [Urinary calculi. Metabolism and diagnosis].

Authors:  R E Hautmann; M Straub
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 7.  [Carefully conducted preanalytic and postanalytic procedures for urine samples. Often neglected in urolithiasis treatment].

Authors:  N Laube; W Berg
Journal:  Urologe A       Date:  2014-01       Impact factor: 0.639

8.  Metabolic stress response patterns in urinary compositions of idiopathic calcium oxalate stone formers, patients with chronic bowel diseases and controls.

Authors:  Wolfgang Berg; Sabine Gayde; Christine Uhlemann; Norbert Laube
Journal:  Urol Res       Date:  2010-05-04

9.  Clinical risk index in urolithiasis.

Authors:  Y M Fazil Marickar; Abiya Salim
Journal:  Urol Res       Date:  2009-07-16

Review 10.  Simplified methods for the evaluation of the risk of forming renal stones and the follow-up of stone-forming propensity during the preventive treatment of stone-formation.

Authors:  Fèlix Grases; Antonia Costa-Bauzá
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.